284 related articles for article (PubMed ID: 22450128)
1. Design and synthesis of 3-(4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridin-2-yl)-1H-quinolin-2-ones as VEGFR-2 kinase inhibitors.
Han SY; Choi JW; Yang J; Chae CH; Lee J; Jung H; Lee K; Ha JD; Kim HR; Cho SY
Bioorg Med Chem Lett; 2012 Apr; 22(8):2837-42. PubMed ID: 22450128
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and SAR of 2-phenoxypyridines as novel c-Jun N-terminal kinase inhibitors.
Song X; Chen W; Lin L; Ruiz CH; Cameron MD; Duckett DR; Kamenecka TM
Bioorg Med Chem Lett; 2011 Dec; 21(23):7072-5. PubMed ID: 22004719
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of substituted 1,2,3-benzotriazines and pyrido[3,2-d]-1,2,3-triazines as inhibitors of vascular endothelial growth factor receptor-2.
Zhao XW; Liu D; Luan SL; Hu GD; Lv JL; Jing YK; Zhao LX
Bioorg Med Chem; 2013 Dec; 21(24):7807-15. PubMed ID: 24189187
[TBL] [Abstract][Full Text] [Related]
4. 2-((1H-Azol-1-yl)methyl)-N-arylbenzamides: novel dual inhibitors of VEGFR-1/2 kinases.
Kiselyov AS; Semenova M; Semenov VV; Piatnitski E
Bioorg Med Chem Lett; 2006 Mar; 16(6):1726-30. PubMed ID: 16364640
[TBL] [Abstract][Full Text] [Related]
5. 3D-QSAR study of tetrahydro-3H-imidazo[4,5-c]pyridine derivatives as VEGFR-2 kinase inhibitors using various charge schemes.
Balupuri A; Balasubramanian PK; Cho SJ
Arch Pharm Res; 2015 Aug; 38(8):1434-42. PubMed ID: 25874606
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of substituted 3-anilino-quinolin-2(1H)-ones as PDK1 inhibitors.
O'Brien NJ; Brzozowski M; Wilson DJ; Deady LW; Abbott BM
Bioorg Med Chem; 2014 Jul; 22(14):3781-90. PubMed ID: 24856302
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of potential Rho-kinase inhibitors based on the chemistry of an original heterocycle: 4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one.
Letellier MA; Guillard J; Caignard DH; Ferry G; Boutin JA; Viaud-Massuard MC
Eur J Med Chem; 2008 Aug; 43(8):1730-6. PubMed ID: 18164518
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of type-II VEGFR-2 inhibitors based on quinoxaline scaffold.
Shahin MI; Abou El Ella DA; Ismail NS; Abouzid KA
Bioorg Chem; 2014 Oct; 56():16-26. PubMed ID: 24922538
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and structure-activity relationships of pyrazine-pyridine biheteroaryls as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors.
Kuo GH; Prouty C; Wang A; Emanuel S; Deangelis A; Zhang Y; Song F; Beall L; Connolly PJ; Karnachi P; Chen X; Gruninger RH; Sechler J; Fuentes-Pesquera A; Middleton SA; Jolliffe L; Murray WV
J Med Chem; 2005 Jul; 48(15):4892-909. PubMed ID: 16033269
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110alpha inhibitors.
Hayakawa M; Kawaguchi K; Kaizawa H; Koizumi T; Ohishi T; Yamano M; Okada M; Ohta M; Tsukamoto S; Raynaud FI; Parker P; Workman P; Waterfield MD
Bioorg Med Chem; 2007 Sep; 15(17):5837-44. PubMed ID: 17601739
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological study of 4-aminopyrimidine-5-carboxaldehyde oximes as antiproliferative VEGFR-2 inhibitors.
Huang S; Li R; Connolly PJ; Xu G; Gaul MD; Emanuel SL; Lamontagne KR; Greenberger LM
Bioorg Med Chem Lett; 2006 Dec; 16(23):6063-6. PubMed ID: 16979339
[TBL] [Abstract][Full Text] [Related]
12. Discovery of N-(2-phenyl-1H-benzo[d]imidazol-5-yl)quinolin-4-amine derivatives as novel VEGFR-2 kinase inhibitors.
Shi L; Wu TT; Wang Z; Xue JY; Xu YG
Eur J Med Chem; 2014 Sep; 84():698-707. PubMed ID: 25064347
[TBL] [Abstract][Full Text] [Related]
13. Discovery and molecular docking of quinolyl-thienyl chalcones as anti-angiogenic agents targeting VEGFR-2 tyrosine kinase.
Rizvi SU; Siddiqui HL; Nisar M; Khan N; Khan I
Bioorg Med Chem Lett; 2012 Jan; 22(2):942-4. PubMed ID: 22200597
[TBL] [Abstract][Full Text] [Related]
14. Structure-based design, synthesis, and evaluation of imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyridine derivatives as novel dual c-Met and VEGFR2 kinase inhibitors.
Matsumoto S; Miyamoto N; Hirayama T; Oki H; Okada K; Tawada M; Iwata H; Nakamura K; Yamasaki S; Miki H; Hori A; Imamura S
Bioorg Med Chem; 2013 Dec; 21(24):7686-98. PubMed ID: 24216091
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of novel 3H-imidazole [4,5-b] pyridine derivatives as selective mTOR inhibitors.
Zhang L; Bu T; Bao X; Liang T; Ge Y; Xu Y; Zhu Q
Bioorg Med Chem Lett; 2017 Aug; 27(15):3395-3398. PubMed ID: 28633896
[TBL] [Abstract][Full Text] [Related]
16. Hit to lead evaluation of 1,2,3-triazolo[4,5-b]pyridines as PIM kinase inhibitors.
Pastor J; Oyarzabal J; Saluste G; Alvarez RM; Rivero V; Ramos F; Cendón E; Blanco-Aparicio C; Ajenjo N; Cebriá A; Albarrán MI; Cebrián D; Corrionero A; Fominaya J; Montoya G; Mazzorana M
Bioorg Med Chem Lett; 2012 Feb; 22(4):1591-7. PubMed ID: 22266039
[TBL] [Abstract][Full Text] [Related]
17. Arylphthalazines: identification of a new phthalazine chemotype as inhibitors of VEGFR kinase.
Piatnitski EL; Duncton MA; Kiselyov AS; Katoch-Rouse R; Sherman D; Milligan DL; Balagtas C; Wong WC; Kawakami J; Doody JF
Bioorg Med Chem Lett; 2005 Nov; 15(21):4696-8. PubMed ID: 16143524
[TBL] [Abstract][Full Text] [Related]
18. Discovery of indenopyrazoles as EGFR and VEGFR-2 tyrosine kinase inhibitors by in silico high-throughput screening.
Usui T; Ban HS; Kawada J; Hirokawa T; Nakamura H
Bioorg Med Chem Lett; 2008 Jan; 18(1):285-8. PubMed ID: 17983745
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and evaluation of novel VEGFR2 kinase inhibitors: discovery of [1,2,4]triazolo[1,5-a]pyridine derivatives with slow dissociation kinetics.
Oguro Y; Cary DR; Miyamoto N; Tawada M; Iwata H; Miki H; Hori A; Imamura S
Bioorg Med Chem; 2013 Aug; 21(15):4714-29. PubMed ID: 23755884
[TBL] [Abstract][Full Text] [Related]
20. DNA-dependent protein kinase (DNA-PK) inhibitors. Synthesis and biological activity of quinolin-4-one and pyridopyrimidin-4-one surrogates for the chromen-4-one chemotype.
Cano C; Barbeau OR; Bailey C; Cockcroft XL; Curtin NJ; Duggan H; Frigerio M; Golding BT; Hardcastle IR; Hummersone MG; Knights C; Menear KA; Newell DR; Richardson CJ; Smith GC; Spittle B; Griffin RJ
J Med Chem; 2010 Dec; 53(24):8498-507. PubMed ID: 21080722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
